[go: up one dir, main page]

DK3943070T3 - Langtidsvirkende formuleringer af bedaquilin - Google Patents

Langtidsvirkende formuleringer af bedaquilin Download PDF

Info

Publication number
DK3943070T3
DK3943070T3 DK21178526.6T DK21178526T DK3943070T3 DK 3943070 T3 DK3943070 T3 DK 3943070T3 DK 21178526 T DK21178526 T DK 21178526T DK 3943070 T3 DK3943070 T3 DK 3943070T3
Authority
DK
Denmark
Prior art keywords
bedaquilin
long
acting formulations
formulations
acting
Prior art date
Application number
DK21178526.6T
Other languages
English (en)
Inventor
Koenraad Jozef Lodewijk Marcel Andries
Esther Dina Guido Basstanie
Maristella Bernini
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK3943070T3 publication Critical patent/DK3943070T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5192Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK21178526.6T 2017-07-14 2018-07-13 Langtidsvirkende formuleringer af bedaquilin DK3943070T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17181354 2017-07-14
EP18167463 2018-04-16
EP18739856.5A EP3651736B1 (en) 2017-07-14 2018-07-13 Long-acting formulations

Publications (1)

Publication Number Publication Date
DK3943070T3 true DK3943070T3 (da) 2024-01-22

Family

ID=62874924

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18739856.5T DK3651736T3 (da) 2017-07-14 2018-07-13 Langtidsvirkende formuleringer
DK21178526.6T DK3943070T3 (da) 2017-07-14 2018-07-13 Langtidsvirkende formuleringer af bedaquilin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK18739856.5T DK3651736T3 (da) 2017-07-14 2018-07-13 Langtidsvirkende formuleringer

Country Status (28)

Country Link
US (2) US11141384B2 (da)
EP (3) EP3943070B1 (da)
JP (3) JP7102500B2 (da)
KR (2) KR102679979B1 (da)
CN (2) CN110869004B (da)
AU (1) AU2018298855B2 (da)
BR (1) BR112020000687A2 (da)
CA (1) CA3069069A1 (da)
CO (1) CO2020000328A2 (da)
CY (1) CY1124782T1 (da)
DK (2) DK3651736T3 (da)
ES (2) ES2891976T3 (da)
FI (1) FI3943070T3 (da)
HR (2) HRP20211450T1 (da)
HU (2) HUE064651T2 (da)
JO (1) JOP20200004B1 (da)
LT (2) LT3943070T (da)
MD (1) MD3651736T2 (da)
PE (1) PE20200336A1 (da)
PH (1) PH12020500076A1 (da)
PL (2) PL3651736T3 (da)
RS (2) RS65207B1 (da)
SA (1) SA520410975B1 (da)
SI (2) SI3651736T1 (da)
SM (2) SMT202100557T1 (da)
UA (1) UA126403C2 (da)
WO (1) WO2019012100A1 (da)
ZA (1) ZA202000215B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3943070T (lt) 2017-07-14 2024-02-12 Janssen Pharmaceutica Nv Ilgo veikimo bedakvilino preparatai
WO2020123336A1 (en) * 2018-12-13 2020-06-18 Qrumpharma Inc. Compositions of bedaquiline, combinations comprising them, processes for their preparation, uses and methods of treatment comprising them
JP2023532982A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ.ベー. 長時間作用型配合物
MX2023000439A (es) * 2020-07-09 2023-02-09 Janssen Pharmaceutica Nv Formulaciones a largo plazo.
JP2023532981A (ja) * 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ.ベー. 長時間作用型配合物
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
TW202423427A (zh) 2022-09-28 2024-06-16 比利時商健生藥品公司 長效配方

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US6495534B2 (en) 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
PT1527050E (pt) * 2002-07-25 2010-06-22 Janssen Pharmaceutica Nv Derivados de quinolina e sua utilização como inibidores de micobactérias
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
ME01445B (me) 2005-05-25 2013-12-20 Janssen Pharmaceutica Nv PROCES ZA PRIPREMU (ALFA S, BETA R)-6-BROMO-ALFA-[2-(DIMETILAMINO)ETIL]-2-METOKSI-ALF A-l-NAFTALENIL-BETA-FENIL-3-KINOLINETANOLA
HUE038797T2 (hu) 2006-06-23 2018-11-28 Janssen Sciences Ireland Uc TMC278 vizes szuszpenziói
UA97813C2 (uk) 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
TW201023912A (en) 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
US9421194B2 (en) 2010-04-05 2016-08-23 Rutgers, The State University Of New Jersey Lung targeting dual drug delivery system
TWI577377B (zh) 2010-09-16 2017-04-11 Viiv醫療保健公司 醫藥組合物
SI2696848T1 (sl) 2011-04-15 2020-10-30 Janssen Pharmaceutica N.V. Liofilizirane zdravilne nanosuspenzije
WO2016022853A1 (en) 2014-08-08 2016-02-11 Pharmacyclics Llc Bruton's tyrosine kinase inhibitor combinations and uses thereof
US20180000810A1 (en) * 2015-01-27 2018-01-04 Janssen Pharmaceutica Nv Dispersible compositions
US10653679B2 (en) * 2015-05-04 2020-05-19 Board Of Trustees Of Michigan State University Compositions and methods for inhibiting bacterial growth
ES2972618T3 (es) 2015-10-14 2024-06-13 The Global Alliance For Tb Drug Dev Inc Composición antibacteriana de combinación y régimen antibacteriano de corta duración que comprende linezolid, bedaquilina y pretomanida
CN108349898B (zh) * 2015-10-20 2021-03-23 浙江海正药业股份有限公司 富马酸贝达喹啉的晶型及其制备方法
EP3634583A4 (en) 2017-06-06 2021-03-03 Merck Sharp & Dohme Corp. Long-action implant for treatment of infectious diseases
LT3943070T (lt) 2017-07-14 2024-02-12 Janssen Pharmaceutica Nv Ilgo veikimo bedakvilino preparatai
JP2023532981A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ.ベー. 長時間作用型配合物
MX2023000439A (es) 2020-07-09 2023-02-09 Janssen Pharmaceutica Nv Formulaciones a largo plazo.
JP2023532982A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ.ベー. 長時間作用型配合物

Also Published As

Publication number Publication date
FI3943070T3 (fi) 2024-01-24
CN110869004A (zh) 2020-03-06
PE20200336A1 (es) 2020-02-14
CN115252548A (zh) 2022-11-01
LT3651736T (lt) 2021-10-11
JP7441276B2 (ja) 2024-02-29
EP3943070A1 (en) 2022-01-26
WO2019012100A1 (en) 2019-01-17
JOP20200004A1 (ar) 2020-01-14
HRP20211450T1 (hr) 2022-01-07
CN110869004B (zh) 2022-06-14
LT3943070T (lt) 2024-02-12
EP3651736B1 (en) 2021-06-23
KR20200028964A (ko) 2020-03-17
AU2018298855A1 (en) 2020-01-16
SI3943070T1 (sl) 2024-03-29
PL3651736T3 (pl) 2021-12-20
RS62362B1 (sr) 2021-10-29
JP2020526538A (ja) 2020-08-31
SMT202100557T1 (it) 2021-11-12
ES2891976T3 (es) 2022-02-01
JOP20200004B1 (ar) 2023-09-17
EP3943070B1 (en) 2023-11-22
UA126403C2 (uk) 2022-09-28
KR20240108542A (ko) 2024-07-09
CO2020000328A2 (es) 2020-01-31
CA3069069A1 (en) 2019-01-17
RS65207B1 (sr) 2024-03-29
JP7102500B2 (ja) 2022-07-19
BR112020000687A2 (pt) 2020-07-14
EP3651736A1 (en) 2020-05-20
HUE055762T2 (hu) 2021-12-28
DK3651736T3 (da) 2021-09-27
EP4356968A2 (en) 2024-04-24
HUE064651T2 (hu) 2024-04-28
JP2022130709A (ja) 2022-09-06
MD3651736T2 (ro) 2021-12-31
PH12020500076A1 (en) 2020-11-09
US12171887B2 (en) 2024-12-24
JP7620692B2 (ja) 2025-01-23
SMT202400033T1 (it) 2024-03-13
PL3943070T3 (pl) 2024-05-06
ZA202000215B (en) 2021-07-28
ES2970801T3 (es) 2024-05-30
SI3651736T1 (sl) 2021-11-30
SA520410975B1 (ar) 2022-07-16
US20210085620A1 (en) 2021-03-25
HRP20240058T1 (hr) 2024-03-29
US20220047522A1 (en) 2022-02-17
EP4356968A3 (en) 2024-07-10
US11141384B2 (en) 2021-10-12
CY1124782T1 (el) 2022-11-25
JP2024038043A (ja) 2024-03-19
KR102679979B1 (ko) 2024-06-28
AU2018298855B2 (en) 2024-07-18

Similar Documents

Publication Publication Date Title
DK3509581T3 (da) Formuleringer af (r)-2-amino-3-phenylpropylcarbamat
DK3688162T3 (da) Formuleringer
DK3377059T3 (da) Hæmmere af cxcr2
DK3943070T3 (da) Langtidsvirkende formuleringer af bedaquilin
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3116533T3 (da) Deletion af dystrophingenexon under anvendelse af genmanipulerede nukleaser
DK3668851T3 (da) Fremgangsmåde til fremstilling af thiocarbonater
DK3368014T3 (da) Nye formuleringer af cannabinoider
DK3302437T3 (da) Stabile cannabinoidformuleringer
DK3185853T3 (da) Inhalerbare pulverformuleringer af alginatoligomerer
EP3442586A4 (en) STABLE PARENTERAL NIMOPIDINE FORMULATION
DK3798222T3 (da) Krystallinsk form af den frie base af lorlatinib
DK3259349T3 (da) Dehydrogenase-katalyseret fremstilling af FDCA
DK3102555T3 (da) Sammensætninger af forbindelser og anvendelser deraf
DK3285756T3 (da) Formuleringer af l-ornithinphenylacetat
DK3457851T3 (da) Derivater af sobetirom
DK3261608T5 (da) Sammensætninger omfattende kombinationer af organiske syrer
EP3364945C0 (en) SOLID FORMULATION
DK3220891T3 (da) Sublingual formulering af riluzol
DK3678644T3 (da) Formuleringer af copanlisib
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3697418T3 (da) Forbedrede formuleringer af bromocriptin
DK3511000T3 (da) Krystallinsk form x2 af grapiprant
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
DK3310331T3 (da) Injicerbare farmaceutiske formuleringer af lefamulin